Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-11-01Clinical Trial Update: Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
A completed clinical trial evaluating Enbrel (etanercept) as a biological treatment for moderate to severe plaque psoriasis, with results po…
-
CLINICAL_TRIALS trial_result · 2021-10-25Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis [Phase 2]
Phase 2 trial assessing long-term safety, tolerability, and efficacy of bimekizumab in chronic plaque psoriasis has completed with results p…
-
CLINICAL_TRIALS trial_result · 2021-10-25Clinical Trial Update: Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
Completed clinical trial evaluating the impact of difficult-to-treat sites on biological response in moderate-to-severe plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2021-10-21Clinical Trial Update: DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial update for DFD01 spray in adolescents with moderate to severe plaque psoriasis has been terminated; results posted in 2021.
-
FDA approval · 2021-10-15FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approves a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC. The approval…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2021-09-30Clinical Trial Update: A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis [Phase 4]
Phase 4 trial of brodalumab (KHK4827) for moderate to severe plaque psoriasis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-09-13Clinical Trial Update: A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis [Phase 2]
Phase 2 double-blind, placebo-controlled trial evaluating belumosudil for moderate-to-severe chronic plaque psoriasis completed with posted …
-
CLINICAL_TRIALS trial_result · 2021-09-08Clinical Trial Update: Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial comparing BCD-057 to Humira in moderate-to-severe plaque psoriasis has been completed.
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 clinical trial evaluating efficacy and safety of a 2 mL auto-injector of secukinumab (300 mg) in moderate to severe plaque psoriasis…
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 study evaluating the efficacy and safety of JTE-451 in moderate to severe plaque psoriasis has completed with results posted.
-
FDA label_change · 2021-08-06FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for ENSTILAR (calcipotriene and betamethone dipropionate) from LEO Pharma Inc., resulting in changes…
-
CLINICAL_TRIALS trial_result · 2021-08-06Clinical Trial Update: Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 trial evaluating JTE-051 for plaque psoriasis was terminated; results posted previously.
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis [Phase 2]
Phase 2 trial update for DRM02 in plaque psoriasis reports safety and efficacy data.
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis [Phase 2]
Phase 2 trial assessing the efficacy of ZPL-3893787 in subjects with plaque psoriasis has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial comparing risankizumab to secukinumab in moderate-to-severe plaque psoriasis completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis [Phase 1, Phase 2]
A clinical trial update for ARQ-151 cream in adults with mild to moderate chronic plaque psoriasis reports safety, pharmacokinetics, and pre…
-
CLINICAL_TRIALS trial_result · 2021-06-25Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]
Phase 3 trial update of ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis completed, with results posted in 2021.
-
FDA approval · 2021-06-17FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for INFLECTRA (infliximab-dyyb) from Pfizer Laboratories Div Pfizer Inc, marking FDA action on a bio…
-
CLINICAL_TRIALS trial_result · 2021-06-07Clinical Trial Update: Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating two secukinumab regimens in patients weighing 90 kg or more with moderate to severe chronic plaque psoriasis; study…
-
FDA approval · 2021-05-28FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for COSENTYX (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2021-05-17Clinical Trial Update: Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy [Phase 3]
Phase 3 trial comparing apremilast to placebo for mild-to-moderate plaque psoriasis. Safety and efficacy results were posted in May 2021.
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 randomized trial evaluating two dosing regimens of BCD-085 for moderate to severe plaque psoriasis; study completed with results pos…
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial update evaluating usability of a risankizumab autoinjector combination product in adults with moderate to severe plaque psoria…
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis [Phase 2]
A Phase 2 safety study comparing spray 188-0551 to the reference listed drug in adults with plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis [Phase 3]
Phase 3 trial update on SHR-1314 assessing efficacy, safety, and pharmacokinetics in moderate-to-severe plaque psoriasis.